AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration ...( AstraZeneca and The University of Texas...),Health

AstraZeneca and The University of Texas M. D. Anderson Cancer Center, a recognized world leader in cancer research, today announced entering into scientific collaboration agreements that will allow for integrated pre-clinical and clinical research on new treatments for cancer, focusing initially on aerodigestive diseases (e.g., lung cancer, head and neck cancers or colorectal cancers).

These renewable, three-year, master agreements establish a framework for collaboration on a variety of initiatives across a range of AstraZeneca oncology products and research projects. The umbrella agreements address pre-clinical and clinical research in a way that will allow the two organizations to more efficiently and effectively work to answer future research questions. The specific terms of the agreements are confidential.

"Establishing a framework for our ongoing relationship will save time and effort when negotiating individual research projects in the future," says Les Hughes, Global Head of Cancer Research. "It is vital that we collaborate effectively with the best cancer research institutions if we are to meet our goals of finding effective treatments for patients with cancer."

AstraZeneca and M. D. Anderson share a mutual goal of designing clinical trials that more efficiently determine the effectiveness of innovative cancer treatments in helping patients. The broad nature of these agreements aim to accomplish this by better integrating pre-clinical and clinical research. Scientists will combine resources and expertise in disease intervention and translational science to address key questions in the lab and later translate those findings to the clinic.

"Integrating ideas with industry earlier in the drug development process will enhance our ability to bring new treatments from the bench to the bedside more rapidly," says Robert Bast, M.D., vice president for translational research at M. D. Anderson. "To make the most rapid progress in th
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
12-Jan-2006

Page: 1 2
Related medicine news :

1. AstraZeneca announces SYMBICORT is now available in the US
2. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
3. M.D. Anderson collaborates with Federal Ministry of Health in Nigeria
4. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
5. M. D. Anderson, BCM, launch research effort targeting asthma and allergic diseases
6. M. D. Anderson teaches the art of aromatherapy to soothe and heal
7. M. D. Anderson: Setting the benchmark in brain tumor treatment
8. International award honors M. D. Anderson President for pioneering research
9. Rice, M. D. Anderson win funds for bench to bed training
10. Newest M.D. Anderson SPORE to fund breast cancer research
11. Red and Charline McCombs contribute $30 million to M. D. Anderson research effort